跳转至内容
Merck
CN

5.32830

Arachidonic Acid, Fungal sp., Sodium Salt

别名:

Arachidonic Acid, Fungal sp., Sodium Salt, 20:4, cis,cis,cis,cis-5,8,11,14-Eicosatetraenoic Acid, Na

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C20H31O2 · Na
化学文摘社编号:
分子量:
326.45
UNSPSC Code:
12352200
MDL number:
Form:
crystalline solid
Assay:
≥99% (TLC and GC)
Solubility:
water: 5 mg/mL
Color:
white
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C20H32O2.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22;/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22);/q;+1/p-1/b7-6-,10-9-,13-12-,16-15-;

InChI key

DDMGAAYEUNWXSI-XVSDJDOKSA-M

assay

≥99% (TLC and GC)

form

crystalline solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

white

solubility

water: 5 mg/mL

storage temp.

−20°C

Quality Level

General description

A cis-polyunsaturated fatty acid found in the plasma membrane. Major component of membrane phospholipids. Following its release by cellular phospholipases, it is enzymatically converted to a variety of inflammatory and vasoactive metabolites, such as prostaglandins (via the cyclooxygenase pathway), leukotrienes (via the lipoxygenase pathway), and epoxides (via the cytochrome P450 pathway). Binds to G-protein α-subunits in a covalent, posttranslational manner. Inhibits Ras-GAP. Stimulates the synthesis of nitric oxide by platelets.
Precursor for prostaglandins, prostacyclin, and thromboxane. Binds to G-protein α-subunits in a covalent, post-translational manner. Inhibits Ras-GAP. Stimulates the synthesis of nitric oxide by platelets. Modulates nitric oxide production by prostaglandin synthesis via the cyclooxygenase pathway.

Biochem/physiol Actions

Cell permeable: no
Primary Target
Ras-GAP
Product does not compete with ATP.
Reversible: no

Packaging

Packaged under inert gas

Preparation Note

Unstable in solution; reconstitute just prior to use.

Other Notes

Hallak, H., et al. 1994. J. Biol. Chem.269, 4713.
Khurana, G., and Bennett, M.R. 1993. Br. J. Pharmacol.109, 480.
Han, J.-W., et al. 1991. Science252, 576.
Radomski, M.W., et al. 1990. Br. J. Pharmacol.101, 325.
Neddleman, P., et al. 1986. Annu. Rev. Biochem.55, 69.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Harmful (C)

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

235.4 °F - closed cup

flash_point_c

113 °C - closed cup

法规信息

新产品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

相关内容

A major focus of breast cancer research is to understand the mechanisms responsible for disease progression and drug resistance. Toward that end, it has been found that approximately two thirds of all human breast carcinomas overexpress the Estrogen Receptor α (ERα) protein and it remains the primary pharmacological target for endocrine therapy1,2. The normal cellular function of ERα is as a transcription factor that mediates a wide variety of physiological processes, many of which are dependent upon phosphorylation of the receptor at specific amino acid residues3,4. Indeed, ERα is known to be phosphorylated at a multitude of different sites, yet how these all correlate to disease remains unclear5. Here, we interrogated multiple sites of ERα for phosphorylation status by screening an extensive panel of different breast cancer patient samples and other non-breast cancer tissue microarray (TMA) slide samples to determine their relevance to disease.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持